Other · developed by Kiora Pharmaceuticals
KIO-201 is a stand-alone therapy that forms a barrier on the ocular surface, reducing mechanical lid friction and protecting the cornea from repeat injury. It is studied in persistent corneal epithelial defects.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05436288 | Phase 2 | Persistent Corneal Epithelial Defect | Completed | KPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Persistent Corneal Epithelial Defect
Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.
See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPRX catalysts and pipeline →